EXHIBIT 107
Calculation of Filing Fee Tables
Form S-3
(Form Type)
Vera Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Newly Registered Securities
Security Type | Security Class Title | Fee Calculation Rule | Amount Registered | Proposed Maximum Offering Price Per Share | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | |||||||
Equity | Class A Common Stock, par value $0.001 per share | Rule 457(o) | (1) | (1) | (1) | |||||||||
Unallocated (Universal) Shelf | Unallocated (Universal) Shelf | Rule 457(o) | (1) | (1) | $9,500,018 | 0.00014760 | $1,402.21 | |||||||
Total Offering Amounts | $9,500,018 | $1,402.21 | ||||||||||||
Total Fees Paid Previously | — | |||||||||||||
Total Fee Offsets | — | |||||||||||||
Net Fee Due | $1,402.21 |
(1) | The Registrant previously registered the offer and sale of certain securities, including its Class A common stock, par value $0.001 per share, having a proposed maximum aggregate offering price of $400,000,000 pursuant to Registration Statement on Form S-3 (File No. 333-265408), which was filed on June 3, 2022 and declared effective by the SEC on June 13, 2022 (the “Prior Registration Statement”). As of the date hereof, a balance of $277,999,996 of such securities remains unsold under the Prior Registration Statement. In accordance with Rule 462(b) under the Securities Act of 1933, as amended, and General Instruction IV(A) of Form S-3, the Registrant is hereby registering the offer and sale of an additional $9,500,018 of its shares of Class A common stock. The additional amount of securities that is being registered for offer and sale represents no more than 20% of the maximum aggregate offering price of the remaining securities available to be sold under the Prior Registration Statement. |